Compare TII & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TII | ALXO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Canada | United States |
| Employees | 167 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.9M | 240.8M |
| IPO Year | N/A | 2020 |
| Metric | TII | ALXO |
|---|---|---|
| Price | $2.31 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.38 | $3.50 |
| AVG Volume (30 Days) | 264.6K | ★ 698.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.20 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $0.41 |
| 52 Week High | $5.65 | $2.66 |
| Indicator | TII | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 54.37 |
| Support Level | $2.09 | $1.44 |
| Resistance Level | $3.14 | $2.27 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 0.00 | 52.94 |
Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.